Monopar Therapeutics (NASDAQ:MNPR) Raised to “Hold” at Wall Street Zen

Monopar Therapeutics (NASDAQ:MNPR) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other brokerages have also issued reports on MNPR. Cantor Fitzgerald lowered shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $109.00 to $119.00 in a research note on Thursday, August 13th. Zacks Research downgraded shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a research note on Tuesday, June 2nd. Barclays reiterated an “overweight” rating and set a $145.00 price objective (up from $128.00) on shares of Monopar Therapeutics in a report on Friday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Monopar Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $120.08.

Monopar Therapeutics Stock Performance

Shares of MNPR stock opened at $110.26 on Friday. Monopar Therapeutics has a fifty-two week low of $45.52 and a fifty-two week high of $124.82. The stock has a 50 day simple moving average of $111.51 and a two-hundred day simple moving average of $79.23. The company has a market cap of $739.84 million, a P/E ratio of -50.81 and a beta of 1.49.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. On average, research analysts predict that Monopar Therapeutics will post -2.94 earnings per share for the current year.

Insider Activity at Monopar Therapeutics

In related news, Director Kim R. Tsuchimoto sold 4,090 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total value of $455,585.10. Following the completion of the sale, the director directly owned 7,396 shares of the company’s stock, valued at approximately $823,840.44. This represents a 35.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the firm’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total value of $351,181.34. Following the transaction, the director owned 23,751 shares in the company, valued at approximately $2,654,649.27. This trade represents a 11.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.70% of the stock is owned by insiders.

Institutional Trading of Monopar Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. bought a new position in shares of Monopar Therapeutics during the third quarter valued at about $28,000. BNP Paribas Financial Markets grew its position in Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares in the last quarter. Sei Investments Co. grew its position in Monopar Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after purchasing an additional 656 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in Monopar Therapeutics in the 4th quarter valued at about $65,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Monopar Therapeutics in the 4th quarter valued at about $86,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company’s programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity.

Monopar’s lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin.